Browsing Tag
Dave Johnson
3 posts
Merck’s $2.75bn acquisition of VelosBio: Strengthening its oncology pipeline
In a strategic move to bolster its oncology portfolio, U.S. pharmaceutical giant Merck & Co. has announced the…
VelosBio initiates Phase 2 trial for ROR1-targeting antibody-drug conjugate VLS-101 in solid tumors
VelosBio, a San Diego-based biopharmaceutical company, has reached a significant milestone in the development of its investigational antibody-drug…
Alliqua BioMedical to acquire Adynxx, forming new clinical-stage pharmaceutical leader
Pennsylvania-based Alliqua BioMedical has announced a significant merger with San Francisco’s Adynxx, aiming to establish a clinical-stage pharmaceutical…